cyrilzakka/clinical-trials huggingface dataset:
Effects of the Individual and Family Self-Management of Fall Prevention Program on Balance Ability and Fall Efficacy Among Chinese With Post-Stroke

This study is about exploring the effectiveness of individual and family self-management (IFSM) fall prevention programs on balance ability and fall efficacy in post-stroke people. The main intervention measures were developed based on the risk and protective factors of fall prevention in post-stroke people, including exercise, environment safety, assistant technology, medication review, and safety in daily activities. The intervention will be implemented in 10 weeks for both patients and their family members. By mastering these skills, post-stroke people may reduce the number of falls after discharge to home.


Eligibility Criteria:
Inclusion Criteria:

* For patients (a) aged 18 years or above; (b) first-ever diagnosed with ischemic stroke; (c) level of impairment assessed by the National Institutes of Health Stroke Scale (NIHSS) scores between 5 to 15 (moderate severity) before entering the experiment; (d) mental state assessed by Mini-Mental State Exam score\&gt; 24; (e) mobility tested by Timed Up and Go ≥12.6 second (walkers or another kinds of gait aid are allowed to be used in the test); (f) motor power of all limbs examined by muscle power assessment grade ≥3; (g) ability to understand Chinese; (h) living with family members; (i) having phones that can use the internet; (j) willing to join the study.

For caregivers: (a) mental state assessed by a Short Portable Mental Status Questionnaire score≥8; (b) the primary caregiver who lives in the same house and takes care of the patients; (c) having phones that can use the internet; (d) willing to participate; and (e) can speak, understand, and write in Chinese

Exclusion Criteria:

* having problems with sensory and/or global aphasia
Sensory Re-learning of the Upper Limb After Stroke

The overall aim of this study is to investigate if sensory re-learning in combination with task-specific training is more effective than task-specific training alone to improve sensory function of the hand, dexterity, the ability to use the hand in daily activities, perceived participation and life satisfaction.

More than half of stroke survivors suffer from sensory impairments of their affected upper limb (UL), which can lead to long term problems to use the UL in daily life, such as personal care, household- and leisure activities. Few studies have evaluated if sensory re-learning in combination with task-specific training can improve the ability to perform daily hand activities and perceived participation. Therefore, there is a need for more studies. This is a single-blinded pilot randomized controlled trial with two treatment arms. Thirty persons with sensory impairments of the UL after stroke will be recruited and randomized to either sensory re-learning in combination with task-specific training or to task-specific training only. The training will consist of 2.5 hours of group training per session, 2 times per week for 5 weeks. Assessments will be conducted pre- and post-training and at 3 months' after the intervention.

Descriptive statistics (mean (SD) or median (min- max) will be used to characterize the study groups. Non-parametric statistics will be used for ordinal data and parametric statistics for continues data. To analyze between group differences, the Mann-Whitney test or Independent sample t-test will be used and Wilcoxon signed ranks test or paired t-test to analyze within group differences. The level of statistical significance will be set at p \< 0.05.

Eligibility Criteria:
Inclusion Criteria:

* sensory impairments (≤5 points in Shape-Texture Identification test) of upper limb after stroke
* ability to grasp and release an object
* be able to understand oral and written information
* 18-80 years of age
* at least 6 months since stroke onset
* be able to walk with or without an assistive device

Exclusion Criteria:

• sensory impairments of the UL due to other diagnosis than stroke
Single Dose Intravenous Iron Isomaltoside in Combination With Oral Iron vs Oral Iron Monotherapy in Patients With Anemia After Postpartum Haemorrhage

The investigator's study is going to compare effectiveness of single dose intravenous iron in combination with oral iron versus oral iron monotherapy in correcting haemoglobin deficit, replenishing iron stores and improving clinical symptoms in women with post-partum anaemia after postpartum hemorrhage without increasing the rate of adverse outcomes.


Eligibility Criteria:
Inclusion Criteria:

* women who underwent spontaneous vaginal delivery with Post partum hemorrhage (PPH) ≥ 500ml OR women who underwent lower segment caesarean section with PPH ≥ 1000 ml
* post PPH haemoglobin level ≤ 10.0 g/dl measured within 48hrs after delivery and stabilisation \& resuscitation.
* ≥ 18 years of age
* Proficient in Malaysian language or English language
* Willingness to consent for blood taking and attending follow-up at 2 weeks and 6 weeks

Exclusion Criteria:

* refused consent to participate in trial
* history of hemolytic anemia, Thalassemia , and sickle cell anemia
* women with signs of sepsis (clinical or laboratory evidence-intrapartum fever \>38.5 degrees with abnormal vital signs, positive blood culture)
* clinical or laboratory evidence of hepatic or renal, cardiovascular and hemolytic abnormalities
* history of active severe acid peptic disorder, esophagitis or hiatus hernia and malabsorption syndrome.
* Severe symptoms of anemia including dyspnoea at rest, angina pectoris, syncope or transient ischemic attacks.
* history of severe asthma, eczema or other atopic allergy
* known allergy to iron
* patients with known immune or inflammatory conditions (e.g. systemic lupus erythematosus, rheumatoid arthritis).
INTERogating Cancer for Etiology, Prevention and Therapy Navigation

This study is being done to identify markers and causes of cancer by analyzing patient's DNA (i.e., genetic material), RNA, plasma, tissues, or other samples that could be informative for patients with cancer. Cancer genetic testing is a series of tests that finds specific changes in cancer cells and normal cells in the body. Researchers may request to access these data as they explore how to better prevent, screen, or treat cancer. This study is also being done to create a biobank (library) of samples and information to learn more about treating cancer. Discovery of genetic variants in patients with cancer could result in opportunities for cancer prevention, earlier diagnosis or better therapy for cancer.


Eligibility Criteria:
Inclusion Criteria:

GROUP A: Germline and Somatic Testing

* Has Mayo Clinic medical record number
* Confirmed cancer diagnosis which is either recurrent, relapsed, refractory, metastatic, or advanced
* Participant aware of cancer diagnosis
* Able to provide informed consent
* Ability to provide blood, saliva, bone marrow aspirate or hair follicle sample
* Ability to provide archived tissue, Note: if tissue unavailable participant may still enroll onto the study for the germline collection, or vice versa, if germline has already been completed may still enroll for somatic tissue testing.

GROUP B: Germline testing only:

* Has Mayo Clinic medical record number
* Confirmed cancer diagnosis
* Participant aware of cancer diagnosis
* Able to provide informed consent
* Ability to provide blood, saliva, or hair follicle sample

Exclusion Criteria:

Note: Women who are pregnant or planning to become pregnant can take part in this study.

GROUP A: Germline and Somatic testing

* Individuals who have situations that would limit compliance with the study requirements
* Institutionalized (i.e. Federal Medical Prison)
* Prior germline genetic testing with a 100+ multi-gene panel within the last 1 year of enrollment, AND/OR
* Prior somatic tissue (250+ gene) testing within the prior 3 months of enrollment

GROUP B: Germline testing only

* Individuals who have situations that would limit compliance with the study requirements
* Institutionalized (i.e. Federal Medical Prison)
* Prior germline genetic testing with a 100+ multi-gene panel within the last 1 year of enrollment
Carotid Atherosclerotic Plaque Load and Neck Circumference

The aim of this study is to establish a deep learning model to automatically detect the presence and scoring of carotid plaques in neck CTA images, and to determine whether this model is compatible with manual interpretations.

Modeling CTA images for carotid artery segments with deep learning method and automatic carotid plaque presence and scoring will be useful and beneficial in clinical practice. The aim of this study is to establish a deep learning model to automatically detect the presence and scoring of carotid plaques in neck CTA images, and to determine whether this model is compatible with manual interpretations.

Eligibility Criteria:
Inclusion Criteria:

* 18 years or older
* Having cranial CTA withdrawn
* Having blood lipids, HbA1c, blood glucose, AST, ALT measured in 3 months before and 3 months after cranial CTA

Exclusion Criteria:

* Thyroid disease
* Having had neck surgery
* Use of corticosteroids for more than 6 months
* Presence of lymph nodes in the anterior neck
* Hypertrophy of neck muscles
Evaluation of the SENSEI® Laparoscopic Tethered Gamma Probe for 99mTc-nanocolloid Sentinel Lymph Node Biopsy in Prostate Cancer

This study is a prospective, open label, single-arm study to examine the performance and safety of the SENSEI® laparoscopic tethered gamma probe in patients undergoing 99mTc-nanocolloid SLNB for prostate cancer (PCa) during RP and ePLND surgery.

Patients scheduled for RP and ePLND using the standard treatment pathways at each centre will have preoperative 99mTc-nanocolloid imaging. RP and ePLND will be conducted as standard of care, with SLNB guided by the SENSEI® laparoscopic tethered gamma probe carried out after RP and prior to ePLND. The first 2 patients per site (N = 10 in total) are considered to be sufficient to enable further familiarisation with the procedure and use of the probe in addition to the usability work and training that the sites did prior to the start of this study. Subsequent patients will be evaluable for the PP population. The primary analysis of diagnostic performance will be performed using the PP population of patients with SLN identified on preoperative imaging


Eligibility Criteria:
Inclusion Criteria:

* Male subjects who are ≥ 18 years of age with histologically proven prostate cancer; and who have signed an informed consent form prior to any study related activity • Subjects who are scheduled for radical prostatectomy with ePLND.

Exclusion Criteria:

* Subjects who have received prior prostate cancer treatment or prior pelvic surgery;

  * Subjects who have an existing medical condition that would compromise their participation in the study;
  * Subjects with a history of hypersensitivity to 99mTc-nanocolloid or any excipients;
  * Subjects who are unable to give voluntary, written informed consent to participate in this study;
  * Subjects who are unable to understand this study and are not willing to complete all the study assessments.
Translating Telephonic Diabetes Self-management Support to Primary Care Practice

The goal of this study is to evaluate the implementation and effectiveness of an intervention to improve diabetes self-management, emotional distress and metabolic control among adults with type 2 diabetes receiving care in primary care practices throughout New York City. The program will be implemented by the New York City Department of Health, through their Primary Care Improvement Project.


Eligibility Criteria:
Inclusion Criteria:

* 21 years of age and older
* Receiving treatment for diabetes at selected primary care practices throughout New York City
* Most recent HbA1c ≥ 7.5% (max 3 months prior to randomization)
* Ability to speak and read English or Spanish (or someone in the household who will read to them)
* Access to a telephone
* Willing to give informed consent to participate and accept random assignment.

Exclusion Criteria:

* Stated intention to move out of the New York City area during the next year
* Mental incapacity (e.g., confusion) evident on first telephone contact by Department of Health staff
* Treatment provider deems that the patient is inappropriate for the trial
Psychotherapy Expectations and Distress Among Mental Health Patients and Their Therapists.

Patients will be recruited from the units of Shalvata MHC: closed and open hospitalization unit, and ambulatory units of Shalvata MHC community clinic. Their therapists will be recruited as well. There will be 4 timepoints measurement: baseline, second week, fourth week and after eight weeks (or discharge). Patients will be addressed through the therapeutic staff and the research team will contact them after a conceptually agreement to participate. A member of the research staff will schedule a meeting explaining the research thoroughly and ask the patient/therapist to sign an informed consent. After signing an informed consent, patients will complete several questionnaires at several time points, whereas their therapists will complete measures as well. All scales will be filled using the Qualtrics platform. In hospitalization unit questionnaires will be filled with the aid of the research coordinator, and in the facilities of Shalvata MHC, in face-to-face interaction. During the face-to-face interaction, in case the patient will report suicidal thoughts or plan to a member of the research staff, the therapeutic staff will be notified immediately. patients at community clinics will fill the first measurement in face-to-face interaction and the rest of the questionnaires independently recieveg a link to their mobile phone.


Eligibility Criteria:
Inclusion Criteria:

* Hebrew mother tongue speakers
* Being treated at Shalvata MHC.

Exclusion Criteria:

* Inability to read or comprehend Hebrew due to any reason.
* Agitative patients
* Acute suicidal patients
* Patients in unstable psychotic state
The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia

This is a 2-year study proposing to examine the effects of aripiprazole on heart health factors such as serum lipids, serum leptin, fasting blood sugar, body weight and blood pressure. This study also examines the safety of switching to aripiprazole with respect to changes in the clinical state, preexisting or emergent side-effects, how the brain processes information and changes in social functioning and quality of life.

This is a 2-yr study proposing to examine the effects of switching subjects from conventional and atypical antipsychotic agents to Aripiprazole on cardiovascular health indices in overweight and obese patients with Schizophrenia or Schizoaffective disorder. Thirty partially remitted patients with Positive and Negative Syndrome Scale (PANSS) score of less than 100, who have body mass index (BMI) of 26 or higher will be switched from their existing antipsychotic to aripiprazole over 2-3 weeks period using a clinician determined cross-tapering approach.The objective of the study is to examine cardiovascular health indices such as serum lipids, serum leptin, fasting blood sugar, body weight and blood pressure. This study also examines the safety of switching to Aripiprazole with respect to changes in clinical state, preexisting or emergent side-effects, how brain processes information and changes in social functioning and quality of life.

Eligibility Criteria:
Inclusion Criteria:

* Male and female subjects ages 18-65 years
* Outpatients and stable partial hospital patients
* Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) diagnosis of schizophrenia or schizoaffective disorder
* No psychiatric hospitalization in 30 days prior to study start
* Partially remitted patients with a PANSS score below 100 at screening
* Currently on a stable dose of only one antipsychotic for at least 30 days prior to study start
* Currently receiving a stable dose of all other psychotropic medications for at least 30 days prior to study start
* BMI greater than 26
* Female patients of childbearing age must be using an acceptable method of birth control for at least 1 month prior to participation in the research study and continue for at least 4 weeks after the final study visit.
* Ability to provide informed consent.

Exclusion Criteria:

* Mental retardation
* Current treatment with clozapine
* Currently enrolled in a weight management program or receiving pharmacological treatment for weight reduction
* Serious or unstable medical illness
* Female patients who are pregnant, lactating, or plan to become pregnant during the study period
* Concurrently receiving treatment with ketoconazole, quinidine, carbamazepine.
Atrial Fibrillation at the Viennese University Emergency Department

The results of this study could imply that a atrial fibrillation registry, as a tool for structured diagnosis and therapy in patients with atrial fibrillation, may improve patient care for this rapidly growing population.

Atrial fibrillation is the most common cardiac arrhythmia and is associated with increased cardiovascular morbidity and mortality, with stroke being an especially important and potentially devastating complication. The number of patients with atrial fibrillation is likely to increase 2.5-fold during the next 50 years, reflecting the growing proportion of elderly individuals. Emergency departments play a central role in diagnosis and treatment (rhythm and rate control, initiation of anticoagulatory therapy for stroke prevention) of atrial fibrillation. Additionally, embolic (e.g. stroke, mesenteric ischemia) complications of atrial fibrillation and bleeding complications (e.g. gastrointestinal and intracranial) of anticoagulatory therapy are likewise treated at emergency departments.

Therefor the investigators hypothesis implies that the atrial fibrillation registry could serve as a tool for structured diagnosis and therapy in patients with atrial fibrillation and therefore may improve patient care. Additionally, diagnostic and therapeutic shortcomings by analyzing registry data may be detected.

Eligibility Criteria:
Inclusion Criteria:

* Patients with atrial fibrillation treated at the Emergency Department of the Medical University of Vienna
* Signed consent

Exclusion Criteria:

* Inclusion criteria not met
Immunoclassification of Psoriasis: a Strategy for Precision Medicine

Through the combination of clinical manifestations and omics, the investigators aim to explore the skin cell atlas in different stages of psoriasis lesions, establish a clinical classification standard for psoriasis, and guide the precise treatment of psoriasis.

Psoriasis is a heterogeneous condition that can affect skin and other structures. Over the past decade, considerable advances have been made both in our understanding of the pathogenesis of psoriasis and in the revolutionized immunotherapy of its diverse manifestations. Psoriasis heterogeneity and its cutaneous microenvironment is the leading cause of resistance in patients.

Novel approaches, including single-cell RNA sequencing technology and CyTOF, are proposed as methodological solutions. By their combination with immunotherapy, we can specifically evaluate the mechanism of psoriasis in the face of immunotherapy agents at the single-cell resolution by detecting the transcriptional activity of cytokines, immune checkpoints, screening neoantigens with high transcription levels, identifying rare cells, and assisting the dissection of the critical immune-metabolic pathways in this complex disease. We aim to improve short-term and long-term precision treatment strategies for patients with psoriasis.

Eligibility Criteria:
Inclusion Criteria:

1.18 to 75 years of age 2.Moderate to severe chronic psoriasis, BSA≥3% 3.Duration of psoriasis≥6 months 4.Patients must be candidate for systemic therapy 5.Informed consent must be obtained 6.For female, ß-hCG test is negative and contraception is accepted

Exclusion Criteria:

1. Having severe infections, including hepatitis, HIV and tuberculosis
2. Having significant allergies to biological agents
3. Having a history of malignancy
4. Refusal of contraception
5. Having serious or unstable/uncontrolled illnesses
Role of Bladder Training During Post-operative Hospital Stay After Radical Hysterectomy in Patients

The objective of the study is to evaluate the impact and the outcome of bladder training during post-operative hospital stay after radical hysterectomy, mainly after neoadjuvant concurrent chemo-radiation therapy for locally advanced cervical cancer.


Eligibility Criteria:
Inclusion Criteria:

- Women who underwent Querleu-Morrow class B2 and class C1 RH were enrolled in this randomized prospective study.

Exclusion Criteria:

-All the patients with preoperative urinary dysfunctions were excluded by study. Other exclusion criteria were surgery of lower urinary tract and psychiatric disease.
Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects

The aim of this trial is to investigate the pharmacodynamic (PD), pharmacokinetic (PK), safety, tolerability, and immunogenicity of efgartigimod co-administered with rHuPH20, and to measure the time to inject the full dose of investigational medicinal product (IMP) of different dose levels of efgartigimod co-administered with a fixed concentration of rHuPH20 by the subcutaneous (SC) route of administration in healthy adult male subjects.


Eligibility Criteria:
Inclusion Criteria:

1. Subject is male, between 18 to 70 years of age
2. Subject is healthy
3. Subject has a body mass index (BMI) between 18 kg/m2 to 30 kg/m2
4. Subject is willing and able to understand the purpose and risks of the trial and provide signed and dated informed consent,
5. Others as defined in the protocol

Exclusion Criteria:

1. Previous participation in clinical trials with efgartigimod and/or any products with rHuPH20.
2. Known hypersensitivity to IMP ingredients or history of a severe allergic or anaphylactic reaction to any drug as determined by the investigator.
3. Known seropositivity or positive test at screening for an active viral infection with Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human immunodeficiency virus (HIV).
4. Known clinically relevant immunological disorders.
5. Known history or any symptom of clinically significant illness in the 6 months before IMP administration.
6. Others as defined in the protocol